ROUND TABLE · 2019

2019 – Regulation of Biodrugs: interchangeability, substitution & switch

Regulation of Biodrugs: interchangeability, substitution & switch

2019-regulation-of-biodrugs-7191296a

About this session

Importance of control and management of the complexity of Biosimilars. It is the tole of the authorities to study the concept of interchangeability and decide on these following comparability studies

- Comparability is demonstrated with quality and bioequivalence studies - Question of the comparator element during comparability tests - What are the best studies for demonstrate comparability?

The decision-maker (authorities) must position himself on the question of interchangeability and the payer on the question of switch / substitution - Importance of also implementing the tools to implement the strategy in the market, that the strategy be applicable

Attending experts

dr-yagoub-ghania-b3ebb6e0

Dr. Yagoub Ghania

Ministry of Health, Population & Hospital Reform Algeria

achouak-ghorab-d8fd6934

Dr. Achouak Ghorab

National Agency of Pharamceutical Products

dr-michael-muenzberg-231a215f

Dr. Michael Muenzberg

dr-valerio-azevedo-62b594ec

Dr. Valderilio Azevedo

EDUMED

dr-s-harninarayana-b59de0c0

Dr. S. Harinarayana Rao

Reliance Life Sciences

pr.-ahlam-abdelaziz-d30f6cfa

Pr. Ahlam Abdelaziz

JFDA

Audience

  • Department of Health and Hospital Reform, Ministry of Health of Algeria, Dr. Yagoub
  • Managers of MOH Affiliated Institutions, ANPP – National Agency of Pharmaceutical Products, Dr. Achouak Ghorab
  • Pharmacovigilance Center Prof. Nadjat Loumi
  • Toxicology Center, Prof. Fatma Zoha Hadjadj Aoul
  • Ministry of Industry
  • The National Council of the Order of Pharmacists
  • The National Union of Community Pharmacists
  • Practicioners
  • Senior managers of companies & representatives of the health sector